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Abstract
Background: Acyclovir has been widely used to treat infections caused by herpes simplex virus (HSV) and varicella
zoster virus (VZV). The common adverse effects of this drug include nausea, diarrhea, headache, dizziness and
mental changes. The immune thrombocytopenia induced by acyclovir is rare.
Case presentation: A 67-year-old Chinese male who was given acyclovir 5 mg kg−1 8 hourly intravenously for
treatment of VZV infection developed severe thrombocytopenia with fist sign in oral cavity within 10 days of
starting using acyclovir. The patient’s condition was improved by stopping using acyclovir and further supportive
treatment. The acyclovir-dependent platelet antibody test showed positive results, which implicated acyclovir as
the causative agent. The final definitive diagnosis of acyclovir-induced immune thrombocytopenia was established
basing on the time correlation between the start of using acyclovir and the onset of symptoms of thrombocytopenia,
combining with excluding of other common causes of thrombocytopenia.
Conclusion: There have been few reports of acyclovir-induced immune thrombocytopenia. This is the first case report
and literature review of acyclovir-induced immune thrombocytopenia, with tongue hematoma as the first sign.
Dentists should never overlook this rare adverse effect of acyclovir, as a rapid and appropriate treatment may prevent
further severe life-threatening complications.
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Background
Acyclovir, an acyclic purine nucleoside analogue, has been
widely used because of its highly potent prohibitive prop-
erties for infections caused by HSV and VZV [1, 2].
Acyclovir has minimal toxicity to normal host cells,
because the drug is only adsorbed by the virus infected
cells [3]. Severe adverse effect like neurotoxicity, kidney
disorders and psychiatric was not common, mostly related
to high dose intravenous administrations [4–6]. Only a
few reports of acyclovir-induced myelosuppressive have
been published [7–9], and so far only two case reports of
acyclovir-induced thrombocytopenic purpura have been
reported [3, 10]. Our patient, a 67-year-old Chinese man
who received acyclovir for the VZV infection, presented
with oral hematomas as the first sign. We believe this is
the first well-documented case report of acyclovir-induced
immune thrombocytopenia as the first sign in oral cavity.
Case presentation
A 67-year-old man who was retired presented to the Oral
Maxillofacial Surgery Department of Nanjing Stomatology
Hospital, Nanjing, Jiangsu, China, with a 10-day history of
a “lump” on the left part of his tongue. The patient felt
pain when eating, and the “lump” gradually grew in size.
There was a similar “lump” on the right side of his tongue,
which then regressed with no treatment. Before having
the “lump” on his tongue, the patient had sought treat-
ment at a general hospital, and was given intravenous
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acyclovir 5 mg kg−1 8 hourly for 7 days because of a VZV
infection. The patient denied fever, hematochezia, melena,
hemoptysis, hematuria, and neurologic symptoms. He had
no history of bibulosity, smoking, systemic diseases, or
drug allergy. His family history, social history, and oral
treatment history were unremarkable. No other drugs
were taken during the treatment of the varicella-zoster
virus infection.
Clinical examination
Extraoral examination: There was no enlargement or
change in texture of the maxillofacial and neck lymph
nodes, and no limitation of mouth opening (mouth
opened to 40 mm). No swelling or deformity of the max-
illofacial area and neck were noted. There were several ec-
chymoses on the patient’s legs and feet (Fig. 1).
Intraoral examination: There were three main lesions
in the patient’s mouth. The first lesion appeared on the
left margin of the tongue, a dark purple hematoma,
1.5 cm × 1 cm in size, with a medium texture and hard
base. The lesion was painful on compression, but did
not change color when pressed. Bleeding at the margin
of the lesion was detected (Fig. 2a and b). The second
lesion was on the left side of the tongue tip, showing a
dark purple spot 0.3 cm in diameter (Fig. 2a). It was not
painful on compression. The third lesion was a 0.5 cm ×
0.5 cm white plaque with a bleeding spot at the center
(Fig. 2c), located on the right margin of the tongue, and
eliciting no pain on compression.
Laboratory test
A complete blood count, performed on the day of
presentation, showed a hemoglobin concentration of
120 g/L (120–160 g/L), a white blood cell count of
8.75 × 103/mm3 (4.6–10.2 × 103/mm3) with 58.1% neu-
trophils (50–70%), 25.8% lymphocytes (20–40%), and
9.6% monocytes (2–10%); the platelet count was 10 ×
109/L (100–300 × 109/L) (Fig. 3). Other laboratory
tests showed normal liver function, a normal electro-
lyte profile, and normal haptoglobin, bilirubin (total
and direct), and lactate dehydrogenase (LDH) levels.
Creatinine clearance was 59.2 mL/min. Coagulation
studies were normal. Tests for cytomegalovirus, hepa-
titis A and B viruses, and Epstein–Barr virus yielded
negative results. The result for platelet factor 4 (PF4)/
heparin antibodies using enzyme-linked immunoassay
(ELISA) was positive. The following serotonin-release
assay (SRA) yielded a negative result. ELISA was also
applied for detection of acyclovir-dependent platelet
antibodies in vitro, which showed positive results.
These findings, taken together with the temporal rela-
tionship between the putative drug (acyclovir) and the on-
set of thrombocytopenia, along with the exclusion of the
other most common known causes of thrombocytopenia,
established a definitive diagnosis of acyclovir-induced im-
mune thrombocytopenia.
Initial treatment included telling the patient to stop
using acyclovir, and giving him 5 units of donor platelets
to elevate his platelet count. The patient was also treated
with oral prednisone 60 mg daily for possible immune
thrombocytopenic purpura (ITP).
The subsequent visits
One week later, the patient came back for a follow-up
visit. We saw that the lesion on the left margin of
tongue had regressed obviously. The lesion was of
medium texture, had a softer base than before, was not
painful on compression, and still had some bleeding
spots on the margin (Fig. 2e). The lesions located on
the left side of the tongue tip and the right margin of
tongue were smaller, and the color had changed from
purple to almost white (Fig. 2d and f ). His platelet
count was elevated to 39 × 109/L (Fig. 3). The third
visit: Another 1 week later, the patient came for a sec-
ond follow-up visit. The lesions located on the left side
of the tongue tip and the right margin of tongue had
disappeared (Fig. 2g and i). The lesion on the left
Fig. 1 Extra-oral examination of patient: purple spots on patient’s
legs and feet
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margin of tongue was smaller, and the color changed from
purple to white, with a soft base and no pain on compres-
sion. The patient’s platelet count was elevated to 98 × 109/L.
Discussion
DITP is a challenging clinical problem that is under-
recognized, difficult to diagnose, and associated with se-
vere bleeding complications [11]. The first report of
DITP was published as early as 1865 [12]. DITP can be
triggered by a wide range of medications. There are more
than 200 drugs, including some herbal medicines, that
have been reported to be causeative of DITP [13, 14]. The
incidence of DITP is not well defined; epidemiologic studies
performed in the US and Europe showed that approximately
10 persons per million are affected by DITP [15–18].
Despite the low frequency, DITP is important to recognize
because of the large number of drugs can be involved and
the large number of patients that can be affected [19].
The etiology of DITP is complex. According to the
mechanism responsible for the thrombocytopenia,
DITP can be divided into two main categories, which
are suppression of platelet production and increasing
in clearance of peripheral platelets. The former one is
caused mostly by myelosuppressive drugs. The latter
one can be further divided into three subtypes: nonim-
mune DITP, immune DITP, and autoimmune DITP
[19]. Most DITPs are thought to be caused by the
second mechanism, which is mediated by a drug-
dependent antibody, and most drugs are thought to
cause thrombocytopenia by a drug-dependent immune
mechanism. How drugs induce platelet antibodies and
how platelets are destroyed by these antibodies are
still poorly understood [14].
Patients who experience an unexpected severe
thrombocytopenia and an acute drop in platelet levels
should be suspected of having DITP. Clinical key fea-
tures of DITP are: 1) extensive petechiae or ecchym-
osis, with markedly low blood platelet levels (frequently
<10 × 109/L), approximately 3 to 10 days after starting a
putative medication [13, 14, 20, 21], and 2) platelet
counts return to normal at approximately 7 days after
Fig. 2 Intraoral examination of the first visit (a-c), the second visit (d-f), and the third visit (g-i)
Fig. 3 Time course of the patient’s platelet count after starting
the treatment
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stopping the putative drug (usually in 1–10 days) [22].
Serious bleeding, including intracranial hemorrhage,
can occur [23], presenting a challenging diagnostic and
management problem.
The diagnosis of DITP is mainly established by the ex-
clusion of all the recognized causes of thrombocytopenia
and the temporal association between the administra-
tion of the putative drug and the development of
thrombocytopenia [10]. A careful, detailed history is
crucial to patient evaluation. The patient should be
asked specifically about drug exposure that can cause
thrombocytopenia, including herbal medicine, tonics,
certain foods, drinks, and health supplements. Aster
and George have developed the clinical criteria and
levels of evidence for diagnosis of DITP [14, 24].
In our case, the patient was given acyclovir as anti-
varicella-zoster virus infection treatment. We first con-
sidered a bone marrow suppression and immunologic
thrombocytopenia, which was associated with viral
infections, including human immunodeficiency virus
(HIV), hepatitides virus (including hepatitis B and C vi-
ruses), Epstein-Barr virus, and cytomegalovirus [25].
The tests for the a forementioned viruses were negative,
and varicella-zoster virus is rarely involved in bone
marrow suppression. From the complete blood test re-
sults, only platelets decreased markedly, and the white
cells and hemoglobin concentration remained normal.
Consequently, it was unlikely to be viral-induced
thrombocytopenia.
As heparin-induced thrombocytopenia (HIT) is the
most common cause of a decrease in platelet count
[13], we considered excluding it, although the patient
did not provide a clear history of having taken heparin.
The result of the PF4/heparin antibody test was posi-
tive. PF4/heparin antibodies are sensitive and can be
seen in some acute diseases, not specifically in HIT.
Thus, we performed the SRA assay, which is considered
the gold standard of diagnosis of HIT. The result of the
SRA array was negative. We decided that HIT was un-
likely to be the cause.
Detection of the drug-dependent antiplatelet antibodies
in blood can be helpful in diagnosis [22, 26], although
waiting for results of this assay is time consuming, and the
test may provide false-negative results. We did the assay
and got a positive result. There was no detectable im-
munoglobulin when the patient’s serum was incubated
with normal platelets without identification, and there
were detectable levels of immunoglobulin when the pa-
tient’s serum was incubated with normal platelets in the
presence of acyclovir.
Based on the exclusion of other etiologies of
thrombocytopenia, platelet count, and the positive anti-
platelet antibodies, and with the temporal relationship be-
tween the acyclovir and the onset of thrombocytopenia,
we could make the diagnosis of acyclovir-induced immune
thrombocytopenia.
For most patients, the appropriate treatment is to stop
the putative drug, herbal medicine, or food, administer-
ing platelet transfusions or other therapies if bleeding is
severe [13, 19, 24]. Based on these principles, initial
treatment included stopping the use of acyclovir and giv-
ing 5 units of donor platelets to for supportive treatment
in our case.
Conclusion
A 67-year-old man developed acyclovir-induced
thrombocytopenia after receiving the drug for 10 days
VZV infection. Tongue hematoma was the first sign
of DITP.
This case highlights that acyclovir could be a causative
drug of DITP and that clinicians should be aware of this
potential adverse reaction. A hematoma in the oral cav-
ity can be the first complaint, and patients may present
to a dentist first. Dentists should be alert to the possibil-
ity of this condition.
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